By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Lysosomal enzymes > Elosulfase alfa > Elosulfase Alfa Dosage
Lysosomal enzymes
https://themeditary.com/dosage-information/elosulfase-alfa-dosage-9151.html

Elosulfase Alfa Dosage

Drug Detail:Elosulfase alfa (Elosulfase alfa [ ee-loe-sul-face-al-fa ])

Drug Class: Lysosomal enzymes

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Mucopolysaccharidosis Type IV

2 mg/kg via IV infusion once a week

Comments:

  • Pretreatment with antihistamines with or without antipyretics is recommended 30 to 60 minutes before starting the infusion.
  • See Other Comments/Administration Advice for recommended dilution volume and infusion rates.

Use: For patients with mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome)

Usual Pediatric Dose for Mucopolysaccharidosis Type IV

5 years or older: 2 mg/kg via IV infusion once a week

Comments:

  • Pretreatment with antihistamines with or without antipyretics is recommended 30 to 60 minutes before starting the infusion.
  • See Other Comments/Administration Advice for recommended dilution volume and infusion rates.

Use: For patients with mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome)

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNING: RISK OF ANAPHYLAXIS

  • Life-threatening anaphylactic reactions reported in some patients during infusions of this drug. Anaphylaxis occurred during infusions, regardless of treatment duration. Patients should be observed closely during and after infusion and healthcare providers should be prepared to manage anaphylaxis. Patients should be advised of the signs/symptoms of anaphylaxis and should seek medical care at once if symptoms occur. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions and require additional monitoring.

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 5 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
For IV infusion: Administer diluted solution using a low-protein-binding infusion set with a low-protein-binding 0.2 micrometer in-line filter

  • Patients weighing less than 25 kg: Infusion volume should be 100 mL delivered over a minimum of 3.5 hours; initial infusion rate should be 3 mL/hr for the first 15 minutes, if tolerated, increase to 6 mL/hr for next 15 minutes; then, continue to increase in 6 mL/hr increments as tolerated not to exceed 36 mL/hr
  • Patients weighing 25 kg or more: Infusion volume should be 200 mL delivered over a minimum of 4.5 hours; initial infusion rate should be 6 mL/hr for the first 15 minutes, if tolerated, increase to 12 mL/hr for next 15 minutes; then, continue to increase in 12 mL/hr increments as tolerated not to exceed 72 mL/hr
  • Infusion rates may be slowed, temporarily stopped, or discontinued in the event of hypersensitivity reactions

Preparation Instructions:
  • Dilute to a final volume of 100 mL (weight less than 25 kg) or 250 mL (weight 25 kg or more) using 0.9% sodium chloride injection
  • Avoid agitation during preparation; gently rotate bag to ensure proper distribution
  • Complete infusion within 48 hours from the time of dilution

Storage requirements:
  • Do not freeze or shake
  • Protect from light
  • Concentrated solution: Store at 2C to 8C (36F to 46F)
  • Diluted solution: If cannot use immediately, may store for up to 24 hours at 2C to 8C (36F to 46F) followed by up to 24 hours at 23C to 27C (73F to 81F)

IV compatibility:
  • Compatible with 0.9% Sodium Chloride Injection, USP
  • Should not be infused with other products in the infusion tubing; compatibility not evaluated

General:
  • Closely observe patients during and after administration; infusions should occur in a setting equipped to treat anaphylaxis.
  • Clinical studies did not include patients 65 years or older so it is unknown whether they respond differently.

Patient advice:
  • Patients/caregivers should understand that anaphylactic and hypersensitivity reactions may occur beyond the infusion time; in the event of a severe reaction, seek immediate medical care.
  • A voluntary Morquio A Registry has been established. For additional information and enrollment: [email protected]
Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by